Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b clinical trial assessing MOS118 to treat Metabolic Obstructive Sleep Apnea

Next Previous
Trial Profile

Phase 1b clinical trial assessing MOS118 to treat Metabolic Obstructive Sleep Apnea

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MOS 118 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Adverse reactions
  • Sponsors Mosanna Therapeutics

Most Recent Events

  • 11 Apr 2023 According to Mosanna Therapeutics media release, US based venture capital fund specializing in sleep, and the German investment firm, High-Tech Grunderfonds (HTGF), have invested in a Seed Extension round. The duo joins founding investor Forty51 Ventures to complete the Seed stage investment syndicate;
  • 20 Jul 2022 New trial record
  • 13 Jul 2022 According to osanna Therapeutics media release, the company has secured seed financing led by Forty51 Ventures to pursue the development of AVE0118 which will be referred to as MOS118 going forward; Mosanna will utilize the funds for formulation and manufacturing optimization and regulatory activities to enable this companys first Phase 1b clinical trial by end-2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top